证券代码：000710 证券简称：贝瑞基因 公告编号：2025-050 特别提示： 1、本次拍卖标的物为成都市贝瑞和康基因技术股份有限公司（以下简称 "贝瑞基因"或"公司"）控股股东之一致行动人侯颖女士持有的本公司 400,000 股股票，占其持有公司股份的比例为 100.00%，占公司总股本的比例 为 0.11%。上述将被司法拍卖的股份为无限售流通股，已被全部质押和司法再 冻结。 成都市贝瑞和康基因技术股份有限公司 2、本次拍卖事项所涉及的股份，为公司于 2025 年 9 月 16 日披露的《关 于控股股东之一致行动人所持公司股份被司法拍卖的进展公告》（公告编号： 2025-049）所述侯颖女士持有的公司400,000股股份于2025年9月12日10:00 时结束后，因在规定时间内无人出价流拍的股份。本次拍卖是侯颖女士持有 的 400,000 股股份的二次拍卖。 关于控股股东之一致行动人所持公司股份将被司法拍卖的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 4、公司目前生产经营情况正常，该事项未对公司正常经营活动产生重大 影响。 公司于近日收到控 ...

Core Points - Chengdu Beirui Hekang Gene Technology Co., Ltd. announced that the judicial auction of 400,000 shares held by its controlling shareholder's concerted actor, Hou Ying, ended on September 12, 2025, with no bids placed, resulting in a failed auction [1] - The shares in question represent 100.00% of Hou Ying's holdings and 0.11% of the company's total share capital, and are unrestricted circulating shares that have been fully pledged and judicially frozen [1] - As of the announcement date, Hou Ying has cumulatively had 19,805,661 shares auctioned judicially, but the company's production and operations remain normal, and the failed auction has not caused significant adverse effects [1] - The shares that failed to auction will be disposed of according to the ruling of the Chengyu Financial Court, and the company will continue to disclose updates on this matter [1]

证券代码：000710 证券简称：贝瑞基因 公告编号：2025-049 成都市贝瑞和康基因技术股份有限公司 关于控股股东之一致行动人所持公司股份被司法拍卖的进展公告 | 股 | 是否为控 | 拍 | 本次被司 | 占其所 | 占公司 | 是否 | 东 | 股股东及 | 拍卖 | 卖 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 法拍卖数 | 持股份 | 总股本 | 为限 | 拍卖日期 | 名 | 其一致行 | 人 | 原 | 量（股） | 比例 | 比例 | 售股 | | 称 | 动人 | 因 | 2025 | 年 | 9 | | | | | | | | | 月 | 11 | 日 | 司 | 成渝 | 侯 | 10:00 | 时起 | 法 | | | | | | 是 | 400,000 | 100.00% | 0.11% | 否 | 金融 | 颖 | 至 | 2025 | 年 | 裁 | 法院 | | | 9 | 月 | 12 | 日 | 定 | 10:00 | 时止 | | | ...

证券代码：000710 证券简称：贝瑞基因 公告编号：2025-048 成都市贝瑞和康基因技术股份有限公司 关于持股5%以上股东所持部分股份被司法强制执行实施结果的公告 控股股东高扬先生保证向本公司提供的信息内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 成都市贝瑞和康基因技术股份有限公司（以下简称"公司"或"贝瑞基因"）于 2025年7月23日披露了《关于持股5%以上股东所持部分股份被司法强制执行的提示性公 告》（公告编号：2025-036），公司控股股东高扬先生在国信证券股份有限公司（以 下简称"国信证券"）开展的股票质押回购业务发生违约，成渝金融法院裁定强制变 现被执行人高扬先生持有的"贝瑞基因"股票不超过3,535,214股（占公司总股本比例 不超过1%），强制执行截止日期为2025年10月14日（以下简称"本次强制执行"）。 近日，公司收到了控股股东高扬先生出具的《关于持股5%以上股东所持部分股份 被强制执行实施完成的告知函》，在本次强制执行期间，高扬先生累计被强制执行 3,535,213股公司股份，占公司总 ...

控股股东高扬先生保证向本公司提供的信息内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 成都市贝瑞和康基因技术股份有限公司（以下简称"贝瑞基因"或"公司"） 于近日接到控股股东高扬先生所持有股份发生变动的通知，现将本次权益变动的 具体情况公告如下： 证券代码：000710 证券简称：贝瑞基因 公告编号：2025-047 成都市贝瑞和康基因技术股份有限公司 关于持股5%以上股东权益变动触及1%整数倍的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 本次权益变动方式 通过证券交易所的集中交易（司法强制执行） ☑ 通过证券交易所的大宗交易 □ 其他 □ 3．本次变动前后，投资者及其一致行动人拥有上市公司权益的股份情况 股份性质 本次变动前持有股份 本次变动后持有股份 股数(股) 占 总 股 本 比 例(%) 股数(股) 占总股本比 例(%) 合计持有股份 28,853,510 8.16 26,455,010 7.48 其中：无限售条件股 份 4,861,968 1.38 2,463 ...

Core Viewpoint - Berry Genomics (000710.SZ) reported a significant decline in revenue and net profit for the first half of 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company achieved an operating revenue of 447 million yuan, representing a year-on-year decrease of 18.91% [1] - The net profit attributable to shareholders of the listed company was -27.24 million yuan [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -28.59 million yuan [1] - The basic earnings per share were -0.0771 yuan [1]

Core Viewpoint - The company experienced a decline in revenue and profit during the reporting period due to industry cycles and intensified market competition, but it remains focused on core business, technological innovation, and market expansion to enhance competitiveness and improve service innovation [3][4]. Company Overview - The company did not change its controlling shareholder or actual controller during the reporting period [3]. - The company plans not to distribute cash dividends or issue bonus shares [2]. Financial Performance - In the first half of 2025, the company achieved revenue of 447,434,341.07 yuan and a net profit attributable to shareholders of -27,242,543.15 yuan, indicating a decline compared to the same period last year [3]. Business Development - The company launched the GENOisi? intelligent platform, leveraging AI in gene detection to enhance healthcare services [4][13]. - The company is advancing sequencing technology and has developed the Vega long-read sequencing platform in collaboration with PacBio, which has completed initial deliveries and testing [4][5]. - The NovaSeq 6000Dx-CN-BG sequencing instrument received medical device registration from the National Medical Products Administration (NMPA), marking a significant step towards domestic production capabilities [5]. Market Expansion - The company is expanding its overseas market presence for reproductive health and genetic disease detection products, with several products receiving EU CE certification [6][9]. - The company is conducting a multi-center prospective clinical cohort study in collaboration with over 30 institutions to optimize screening programs and promote clinical application [8]. Research and Development - The company has established partnerships with over 3,000 universities, research institutes, and hospitals, contributing to the publication of over 22,000 research papers [10]. - The company is enhancing its multi-omics product research and has optimized its Fiber-seq multi-omics solution to expand its applicability [10]. Laboratory Development - The company’s laboratories have achieved recognition from authoritative institutions, passing various quality evaluation projects and maintaining compliance with international standards [12]. AI Integration - The GENOisi? intelligent platform integrates AI to support clinical decision-making in disease prediction and diagnosis, marking a shift towards a collaborative clinical intelligence model [13][14]. - The BerryChat intelligent Q&A model has been successfully deployed in over a hundred medical institutions, enhancing the efficiency of clinical report processing [14].

Core Viewpoint - The company, Berry Genomics, has signed a maximum guarantee contract with Hangzhou United Bank for a credit facility of 40 million yuan for its wholly-owned subsidiary, Hangzhou Berry [1] Group 1 - The total amount of external guarantees provided by the company and its subsidiaries is 307 million yuan, which includes the recent guarantee [1] - This total guarantee amount represents 18.28% of the company's most recent audited net assets [1]

成都市贝瑞和康基因技术股份有限公司 2025 年半年度财务报告全文 成都市贝瑞和康基因技术股份有限公司 2025 年半年度财务报告 2025 年 8 月 1 成都市贝瑞和康基因技术股份有限公司 2025 年半年度财务报告全文 财务报告 一、审计报告 半年度报告是否经过审计 □是 否 公司半年度财务报告未经审计。 二、财务报表 财务附注中报表的单位为：元 1、合并资产负债表 编制单位：成都市贝瑞和康基因技术股份有限公司 2025 年 06 月 30 日 单位：元 | 项目 | 期末余额 | 期初余额 | | --- | --- | --- | | 流动资产： | | | | 货币资金 | 359,908,471.56 | 383,071,864.35 | | 结算备付金 | | | | 拆出资金 | | | | 交易性金融资产 | 10,479,041.92 | 17,032,640.72 | | 衍生金融资产 | | | | 应收票据 | 6,414,646.08 | 2,587,200.00 | | 应收账款 | 659,878,630.79 | 692,131,312.99 | | 应收款项融资 | | ...

成都市贝瑞和康基因技术股份有限公司 2025 年半年度非经营性资金占用及其他关联资金往来情况汇总表 法定代表人： 高扬 主管会计工作的负责人： 王冬 会计机构负责人： 高莉 | 非经营性资金占用 | 资金占用方 名称 | 占用方与上 市公司的关 联关系 | 上市公司核算的会计科目 | 2025 年期 初往来资 金余额 | 2025 年 1-6 月 往来累 计发生 金额 （不含 利息） | 2025 年 1-6 月 往来资 金的利 息(如 有) | 2025 年 1-6 月偿还累计 发生金额 | 2025 年 6 月 30 日 往来资金余额 | 占用形成 原因 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 控股股东、实际控 | | | | | | | | | | | | 制人 及其附属企业 | | | | | | | | | | | | 小计 | - | - | - | | | | | | - | - | | 前控股股东、实际 | | | | | | | | | | | | 控制人 | | | | | ...